Biotech Investment Opportunities: Spotlight on CrystecPharma and AMLo Biosciences

On 26th March, Bionow's Investment Showcase webinar series returned with innovative technologies from member companies CrystecPharma and AMLo Biosciences.

Both companies are supported by world-class teams with comprehensive expertise in the Life Sciences sector and clear strategies.

During the Investment Showcase the two companies presented their projects to a virtual audience of investors, seeking funding to advance their initiatives.

About the Investment Showcase webinars

As we all know, one of the main challenges for all Life Science companies is raising investment. This is where the Investment Showcase webinars can play a useful role, as they facilitate the connection and introduction of member companies to investors. Over the years, Bionow has built up a community of investors, and this series aims to leverage these connections to the benefit of member companies.

About CrystecPharma and AMLo Biosciences

Both companies offer investors the opportunity to support exciting and innovative technologies, with burgeoning global markets, clear development pathways and exit strategies.

• CrystecPharma is a crystal and particle engineering company applying its proprietary and award-winning mSAS® (modified Supercritical Anti-Solvent) technology to enable small and large molecules to be manufactured in ways that greatly enhance their therapeutic performance, thereby transforming the quality of life for many patients. Crystec applies its technology to develop innovative therapeutics in areas of high unmet need. 

 

• AMLo Biosciences is a female-founded, female-led diagnostic company developing innovative products for skin cancer indications. Their first product for early-stage melanoma is on the market in UK and US and their pipeline of related AI enabled products are in late validation ready for launch in 2026. They are raising a Series A round of £10m to advance their product development pipeline, set up a UK based CLIA lab to service the US market directly, and expand their sales and marketing efforts in their key markets. This is an exciting opportunity to invest in a company with derisked technology, evidence of early adoption in two key markets, with an anticipated exit by acquisition in the next 24 months.

Each company delivered a 15–20-minute pitch, showcasing their data and vision, and provided opportunities for follow-up discussions.

The pitches can be viewed in full here.
 
Bionow plans further Investment Showcases in 2025. Members with investment opportunities can contact the Membership Team to be featured in upcoming events.